JP2021518415A5 - - Google Patents
Info
- Publication number
- JP2021518415A5 JP2021518415A5 JP2020550856A JP2020550856A JP2021518415A5 JP 2021518415 A5 JP2021518415 A5 JP 2021518415A5 JP 2020550856 A JP2020550856 A JP 2020550856A JP 2020550856 A JP2020550856 A JP 2020550856A JP 2021518415 A5 JP2021518415 A5 JP 2021518415A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable sequence
- seq
- antibody
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023196493A JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647546P | 2018-03-23 | 2018-03-23 | |
| US62/647,546 | 2018-03-23 | ||
| PCT/US2019/022444 WO2019182888A1 (en) | 2018-03-23 | 2019-03-15 | Human pd-l2 antibodies and methods of use therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196493A Division JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518415A JP2021518415A (ja) | 2021-08-02 |
| JP2021518415A5 true JP2021518415A5 (https=) | 2022-02-09 |
| JP7390301B2 JP7390301B2 (ja) | 2023-12-01 |
Family
ID=67987459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550856A Active JP7390301B2 (ja) | 2018-03-23 | 2019-03-15 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
| JP2023196493A Active JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023196493A Active JP7624497B2 (ja) | 2018-03-23 | 2023-11-20 | ヒトｐｄ－ｌ２抗体およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11976128B2 (https=) |
| EP (1) | EP3768298A4 (https=) |
| JP (2) | JP7390301B2 (https=) |
| CN (2) | CN119101158A (https=) |
| AU (2) | AU2019239620B2 (https=) |
| CA (1) | CA3092695A1 (https=) |
| WO (1) | WO2019182888A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| CN119101158A (zh) * | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| SG11202009258RA (en) | 2018-03-23 | 2020-10-29 | Univ Texas | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| AU2024214278A1 (en) * | 2023-02-04 | 2025-08-28 | Mabtree Biologics Ag | Human anti-pd-l2 antibody and its uses thereof |
| EP4626931A1 (en) * | 2023-09-17 | 2025-10-08 | Ji Yan Biomedical Co., Ltd | Recombinant antibodies and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20040131613A1 (en) | 2003-01-08 | 2004-07-08 | Watkins Jeffry D. | TNF-alpha binding molecules |
| EP1633785B1 (en) | 2003-05-21 | 2012-11-28 | Medarex, Inc. | Human monoclonal antibodies against bacillusanthracis protective antigen |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006004988A2 (en) | 2004-06-30 | 2006-01-12 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1928912A4 (en) | 2005-09-07 | 2010-02-24 | Medimmune Inc | EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS |
| US8575070B2 (en) | 2006-02-20 | 2013-11-05 | Phylogica Limited | Methods of constructing and screening libraries of peptide structures |
| CL2008001071A1 (es) | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| EP2497783A3 (en) | 2007-09-26 | 2013-04-17 | U3 Pharma GmbH | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| US8552154B2 (en) * | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| PT3904391T (pt) | 2010-03-10 | 2024-10-14 | Genmab As | Anticorpos monoclonais contra c-met |
| EP2582725A4 (en) * | 2010-06-16 | 2014-05-07 | Us Gov Health & Human Serv | ANTI-DR4 AGONIST ANTIBODY |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CN111499755A (zh) * | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
| JP6859259B2 (ja) | 2014-11-19 | 2021-04-14 | ジェネンテック， インコーポレイテッド | ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用 |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CA2977544C (en) | 2015-03-06 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016160792A1 (en) | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| WO2017053250A1 (en) * | 2015-09-21 | 2017-03-30 | Merck Sharp & Dohme Corp. | Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| EP4354146B1 (en) | 2015-10-19 | 2026-04-15 | Takeda Pharmaceutical Company Limited | Immunoassay for the detection of cleaved high molecular weight kininogen |
| WO2017106453A1 (en) | 2015-12-17 | 2017-06-22 | University Of Maryland, Baltimore County | A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| CN109071636A (zh) | 2016-03-29 | 2018-12-21 | 斯特库比股份有限公司 | 用于选择特异性结合糖基化免疫检查点蛋白的抗体的方法 |
| WO2017185037A1 (en) | 2016-04-22 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| WO2017200796A1 (en) | 2016-05-17 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Engineered pd-1 variants |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN106957823A (zh) | 2016-12-28 | 2017-07-18 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l2蛋白单克隆抗体及其用途 |
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| CN119101158A (zh) * | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| SG11202009258RA (en) | 2018-03-23 | 2020-10-29 | Univ Texas | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
-
2019
- 2019-03-15 CN CN202411090419.0A patent/CN119101158A/zh active Pending
- 2019-03-15 JP JP2020550856A patent/JP7390301B2/ja active Active
- 2019-03-15 CN CN201980021120.0A patent/CN111902156B/zh active Active
- 2019-03-15 US US17/040,269 patent/US11976128B2/en active Active
- 2019-03-15 CA CA3092695A patent/CA3092695A1/en active Pending
- 2019-03-15 AU AU2019239620A patent/AU2019239620B2/en active Active
- 2019-03-15 WO PCT/US2019/022444 patent/WO2019182888A1/en not_active Ceased
- 2019-03-15 EP EP19771524.6A patent/EP3768298A4/en active Pending
-
2023
- 2023-11-20 JP JP2023196493A patent/JP7624497B2/ja active Active
-
2024
- 2024-03-20 US US18/611,087 patent/US12428489B2/en active Active
-
2025
- 2025-09-10 US US19/324,749 patent/US20260008866A1/en active Pending
-
2026
- 2026-04-07 AU AU2026202554A patent/AU2026202554A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518415A5 (https=) | ||
| CN113748133B (zh) | 肿瘤治疗剂及其应用 | |
| JP2021518390A5 (https=) | ||
| CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| JP2022515318A (ja) | 抗体及びその用途 | |
| JP2019527553A5 (https=) | ||
| KR20100044212A (ko) | 새로운 ｃ-Ｍｅｔ 이중합을 저해하는 항체들 및 그들의 용도들 | |
| JP2023540526A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| CN108084265B (zh) | 特异性结合人的5t4抗原的全人源单域抗体及其应用 | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP7836033B2 (ja) | Ｇｐｒｃ５ｄ抗体及びその応用 | |
| JP2021528047A5 (https=) | ||
| JP2018520334A5 (https=) | ||
| CN107001452B (zh) | 用于治疗癌症的抗ck8抗体 | |
| JP2021517459A5 (https=) | ||
| JP2023509373A5 (https=) | ||
| JP2018513141A5 (https=) | ||
| CN112969715B (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
| CN116284407A (zh) | 一种抗gucy2c抗体或其抗原结合片段及其用途 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| JP2020515286A5 (https=) | ||
| CN108290942A (zh) | 与人及小鼠信号素3a交联的抗体及其用途 |